Cargando…

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis

OBJECTIVE: Progestin based therapy is the preferred option for fertility-sparing treatment of reproductive-age women with preserved fertility in endometrial hyperplasia (EH) or early endometrial cancer (EEC). Our objective was to investigate whether metformin could enhance the efficacy of progestin-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Fengping, Li, Yinguang, Zhao, Yunhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320576/ https://www.ncbi.nlm.nih.gov/pubmed/37415671 http://dx.doi.org/10.3389/fendo.2023.1139858

Ejemplares similares

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

Progestin and Nuclear Progestin Receptor Are Essential for Upregulation of Metalloproteinase in Zebrafish Preovulatory Follicles
por: Liu, Dong Teng, et al.
Publicado: (2018)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system
por: Kim, Da Hee, et al.
Publicado: (2017)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis
por: Zhang, Yu-Fei, et al.
Publicado: (2023)

Progestin-Primed Ovarian Stimulation Protocol for Patients With Endometrioma
por: Yang, Ai-Min, et al.
Publicado: (2022)

Editorial: Recent advances in progestin-primed ovarian stimulation
por: Chen, Qiuju
Publicado: (2022)

The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer
por: Guan, Jun, et al.
Publicado: (2022)

Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
por: Kim, Mi Kyoung, et al.
Publicado: (2020)

Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma
por: Newtson, A.M., et al.
Publicado: (2017)

Progestins Related to Progesterone and Testosterone Elicit Divergent Human Endometrial Transcriptomes and Biofunctions
por: Houshdaran, Sahar, et al.
Publicado: (2020)

Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB
por: Cui, Yunxia, et al.
Publicado: (2021)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta‐analysis
por: van Weelden, Willem Jan, et al.
Publicado: (2022)

The progestin revolution 2: progestins are now a dominant player in the tight interlink between contraceptive protection and bleeding control—plus more
por: Shoupe, Donna
Publicado: (2023)

Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis
por: Hu, Jia-Li, et al.
Publicado: (2022)

Prominent decidualization following progestin treatment for endometrial hyperplasia and carcinoma as a mimic of large residual tumor: A cautionary tale
por: Hu, Yang, et al.
Publicado: (2021)

Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer
por: Falcone, Francesca, et al.
Publicado: (2017)

Prognostic factors of oncologic outcomes after fertility-preservative management with progestin in early-stage of endometrial cancer
por: Roh, Hyun Jin, et al.
Publicado: (2021)

Recurrent Endometrial Stromal Sarcoma: Treatment with a Progestin and Gonadotropin Releasing Hormone Agonist
por: duPont, Nefertiti Chianti, et al.
Publicado: (2010)

Identification and Validation of MSX1 as a Key Candidate for Progestin Resistance in Endometrial Cancer
por: Yang, Linlin, et al.
Publicado: (2020)

Partial ablation of endometrial glands in dogs after exposure to progestin during the neonatal period
por: Teixeira, Natália Soares, et al.
Publicado: (2018)

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins
por: Kulkarni, A., et al.
Publicado: (2023)

Response to comment on: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB
por: Cheng, Yali, et al.
Publicado: (2022)

Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report
por: Maenohara, Shoji, et al.
Publicado: (2020)

Letter to editor in response to: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling
por: Mohammed, Ghada, et al.
Publicado: (2021)

Involvement of Membrane Progestin Receptor Beta (mPRβ/Paqr8) in Sex Pheromone Progestin-Induced Expression of Luteinizing Hormone in the Pituitary of Male Chinese Black Sleeper (Bostrychus Sinensis)
por: Zhang, Yu Ting, et al.
Publicado: (2018)

Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience
por: Wang, Yang, et al.
Publicado: (2019)

FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt
por: Dong, Jing, et al.
Publicado: (2017)

Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1
por: Yang, Yuan, et al.
Publicado: (2017)

Study of the Characterization of Side Population Cells in Endometrial Cancer Cell Lines: Chemoresistance, Progestin Resistance, and Radioresistance
por: Liu, Bing-jie, et al.
Publicado: (2020)

Prenatal Progestin Exposure-Mediated Oxytocin Suppression Contributes to Social Deficits in Mouse Offspring
por: Huang, Saijun, et al.
Publicado: (2022)

Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis
por: Li, Miaomiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4jsi6jqfs331otuv39tu43lghe